Biologics for Autoimmune Diseases

The specificity, efficacy and safety profiles of biologics have traditionally made them good candidates for the treatment of autoimmune diseases. Emerging genetic understandings of the mechanisms of these complex disorders are now being combined with exciting new therapeutic formats and strategies in a renewed wave of attention for the use of biotherapeutics in this therapeutic area.

Bispecific and combination therapeutics will provide improved efficacy by impacting multiple targets and processes. Development of biosimilars and biobetters in this space will build on the success of proven therapeutics, while new technologies will offer expanded options for the application of promising validated targets from the past that were not advanced to the market.

The inaugural Biologics for Autoimmune Diseases presents a focused meeting that will track current clinical progress in the major autoimmune diseases, and then offer an exciting exploration of ways in which the industry is applying new science and technology in the development of a next generation of effective and safe therapeutics.

Set in the context of the 10th annual PEGS, attendees of this meeting will join more than 1,500 colleagues working in the fields of protein engineering and biologics development, offering unprecedented opportunities for networking and scientific collaboration.